Larson Financial Group’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-78
| Closed | -$6.33K | – | 3486 |
|
|
2025
Q1 | $6.33K | Buy |
78
+40
| +105% | +$3.24K | ﹤0.01% | 1807 |
|
|
2024
Q4 | $3.42K | Sell |
38
-61
| -62% | -$5.49K | ﹤0.01% | 1745 |
|
|
2024
Q3 | $9.78K | Buy |
99
+57
| +136% | +$5.63K | ﹤0.01% | 1477 |
|
|
2024
Q2 | $3.89K | Buy |
42
+33
| +367% | +$3.06K | ﹤0.01% | 1484 |
|
|
2024
Q1 | $854 | Hold |
9
| – | – | ﹤0.01% | 1475 |
|
|
2023
Q4 | $804 | Sell |
9
-1,426
| -99% | -$127K | ﹤0.01% | 1505 |
|
|
2023
Q3 | $105K | Sell |
1,435
-513
| -26% | -$37.5K | 0.01% | 448 |
|
|
2023
Q2 | $162K | Buy |
1,948
+343
| +21% | +$28.5K | 0.02% | 347 |
|
|
2023
Q1 | $122K | Sell |
1,605
-1,471
| -48% | -$112K | 0.01% | 403 |
|
|
2022
Q4 | $255K | Buy |
3,076
+1,480
| +93% | +$123K | 0.03% | 268 |
|
|
2022
Q3 | $127K | Sell |
1,596
-2,017
| -56% | -$161K | 0.02% | 330 |
|
|
2022
Q2 | $268K | Buy |
3,613
+1,958
| +118% | +$145K | 0.05% | 157 |
|
|
2022
Q1 | $149K | Hold |
1,655
| – | – | 0.02% | 231 |
|
|
2021
Q4 | $185K | Hold |
1,655
| – | – | 0.03% | 202 |
|
|
2021
Q3 | $208K | Sell |
1,655
-19
| -1% | -$2.39K | 0.04% | 147 |
|
|
2021
Q2 | $227K | Buy |
1,674
+19
| +1% | +$2.58K | 0.05% | 120 |
|
|
2021
Q1 | $225K | Buy |
1,655
+1,485
| +874% | +$202K | 0.07% | 103 |
|
|
2020
Q4 | $24K | Hold |
170
| – | – | 0.01% | 339 |
|
|
2020
Q3 | $19K | Buy |
170
+44
| +35% | +$4.92K | 0.01% | 339 |
|
|
2020
Q2 | $14K | Buy |
126
+10
| +9% | +$1.11K | 0.01% | 337 |
|
|
2020
Q1 | $9K | Buy |
+116
| New | +$9K | 0.01% | 310 |
|